Antigen-MHC Nanoparticles for Gut Inflammation Without Immunosuppression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inflammatory bowel disease (IBD) compromise the patient's immunity, posing risks of infection and disease, necessitating the development of target therapies that can suppress chronic inflammation without immunosuppression.
Innovation Solution
Administering an antigen-MHC-nanoparticle complex derived from gastrointestinal tract microbes to activate and amplify endogenous anti-inflammatory responses, thereby accumulating anti-inflammatory T cells and inducing an anti-inflammatory response in tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If immunosuppressives are used to treat inflammatory bowel disease, then inflammation is suppressed, but the patient's overall immunity is compromised
Solution Approach 1:
The patent segments the immune response by targeting only the inflammatory pathway through specific antigens and T cell subsets (regulatory T cells), while leaving the overall immune system intact. This is achieved by using antigen-specific therapies that modulate local inflammation without causing systemic immunosuppression, thus resolving the contradiction between suppressing inflammation and maintaining immunity.
Solution Approach 2:
The invention applies local quality by directing therapeutic effects to specific tissues affected by inflammation (e.g., gastrointestinal tract) through antigen-specific mechanisms. The therapy acts locally on inflamed tissues via antigen-presenting cells and tissue-resident T cells, rather than causing global immunosuppression, thereby suppressing inflammation locally while preserving systemic immunity.
2Reliability
If target therapies are developed to treat inflammation without immunosuppression, then immunity is preserved, but the complexity of the therapy increases
Solution Approach 1:
The patent employs self-service by harnessing the body's own immune mechanisms to treat inflammation. Antigen-specific therapies utilize endogenous antigen-presenting cells, T cell activation, and regulatory T cell recruitment to achieve anti-inflammatory effects without requiring complex external immunosuppressive agents. The body's immune system serves itself to resolve inflammation while maintaining overall immunity.
Solution Approach 2:
The invention uses intermediaries in the form of specific antigens and antigen-presenting cells that mediate between the therapeutic intervention and the immune response. These intermediaries enable targeted modulation of inflammatory responses through well-defined immunological pathways, providing a mechanistically clear and relatively simple approach compared to broad immunosuppression.
Data Source
AI summary
This disclosure provides therapeutic compositions and methods for inducing an anti-inflammatory response and/or treating inflammation in the gastrointestinal tract and/or accumulating gut microbial antigen-specific anti-inflammatory T cells in a patient in need thereof.